当前位置: X-MOL 学术Int. J. Immunogenet. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started
International Journal of Immunogenetics ( IF 2.2 ) Pub Date : 2020-10-28 , DOI: 10.1111/iji.12517
Milena Ivanova 1 , Velizar Shivarov 2
Affiliation  

The implementation of the immune checkpoint blockade as a therapeutic option in contemporary oncology is one of the significant immunological achievements in the last century. Constantly accumulating evidence suggests that the response to immune checkpoint inhibitors (ICIs) is not universal. Therefore, it is critical to identify determinants for response, resistance and adverse effects of immune checkpoint therapy that could be developed as prognostic and predictive markers. Recent large scale analyses of cancer genome data revealed the key role of HLA class I and class II molecules in cancer immunoediting, and it appears that HLA diversity can predict response to ICIs. In the present review, we summarize the emerging data on the role of HLA germline variations as a marker for response to ICIs.

中文翻译:

HLA 基因分型符合对免疫​​检查点抑制剂预测的反应:一个故事才刚刚开始

在当代肿瘤学中实施免疫检查点阻断作为一种治疗选择是上个世纪重要的免疫学成就之一。不断积累的证据表明,对免疫检查点抑制剂 (ICIs) 的反应并不普遍。因此,确定免疫检查点疗法的反应、抵抗和不良反应的决定因素至关重要,这些因素可以开发为预后和预测标志物。最近对癌症基因组数据的大规模分析揭示了 HLA I 类和 II 类分子在癌症免疫编辑中的关键作用,而且 HLA 多样性似乎可以预测对 ICI 的反应。在本综述中,我们总结了有关 HLA 种系变异作为 ICI 反应标志物作用的新数据。
更新日期:2020-10-28
down
wechat
bug